Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-02-18 4:15 pm Purchase |
2025-02-11 | 13G | Xilio Therapeutics, Inc. XLO |
AbbVie Inc. ABBV |
4,347,826 9.000% |
4,347,826 (New Position) |
Filing History |
| 2024-12-19 4:15 pm Purchase |
2024-12-18 | 13G | Xilio Therapeutics, Inc. XLO |
GILEAD SCIENCES INC GILD |
9,105,451 19.900% |
1,759,978 (+23.96%) |
Filing History |
| 2024-11-14 5:44 pm Purchase |
2024-09-30 | 13G | Xilio Therapeutics, Inc. XLO |
Bain Capital Life Sciences Fund II, L.P. | 4,566,817 11.000% |
3,218,135 (+238.61%) |
Filing History |
| 2024-11-14 4:30 pm Sale |
2024-09-30 | 13G | Xilio Therapeutics, Inc. XLO |
Atlas Venture Fund XI, L.P. | 0 0.000% |
-2,023,402 (Position Closed) |
Filing History |
| 2024-11-12 4:50 pm Unchanged |
2024-09-30 | 13G | Xilio Therapeutics, Inc. XLO |
Rock Springs Capital Management LP | 3,003,259 6.830% |
0 (Unchanged) |
Filing History |
| 2024-11-12 10:40 am Sale |
2024-11-08 | 13G | Xilio Therapeutics, Inc. XLO |
FMR CORP | 1,395,853 3.175% |
-511,818 (-26.83%) |
Filing History |
| 2024-09-27 9:36 pm Purchase |
2024-06-07 | 13G | Xilio Therapeutics, Inc. XLO |
GKCC LLC | 7,000,000 15.900% |
7,000,000 (New Position) |
Filing History |
| 2024-07-31 07:46 am Unchanged |
2024-07-31 | 13G | Xilio Therapeutics, Inc. XLO |
TAKEDA PHARMACEUTICAL CO LTD | 1,475,121 4.000% |
0 (Unchanged) |
Filing History |
| 2024-04-05 4:31 pm Purchase |
2024-03-27 | 13G | Xilio Therapeutics, Inc. XLO |
GILEAD SCIENCES INC GILD |
7,345,473 19.900% |
7,345,473 (New Position) |
Filing History |
| 2024-04-05 2:51 pm Purchase |
2024-03-27 | 13G | Xilio Therapeutics, Inc. XLO |
Rock Springs Capital Management LP | 3,003,259 8.710% |
1,562,500 (+108.45%) |
Filing History |
| 2024-02-14 2:12 pm Purchase |
2023-12-31 | 13G | Xilio Therapeutics, Inc. XLO |
Rock Springs Capital Management LP | 1,440,759 5.230% |
1,440,759 (New Position) |
Filing History |
| 2024-02-06 4:04 pm Sale |
2024-01-02 | 13G | Xilio Therapeutics, Inc. XLO |
Octagon Capital Advisors LP | 0 0.000% |
-1,785,000 (Position Closed) |
Filing History |
| 2024-02-05 4:01 pm Sale |
2023-12-31 | 13G | Xilio Therapeutics, Inc. XLO |
Octagon Capital Advisors LP | 1,785,000 6.480% |
-640,000 (-26.39%) |
Filing History |
| 2023-04-10 4:57 pm Purchase |
2023-03-30 | 13G | Xilio Therapeutics, Inc. XLO |
MRL Ventures Fund LLC | 1,483,414 5.400% |
1,483,414 (New Position) |
Filing History |
| 2023-02-09 08:14 am Sale |
2023-02-09 | 13G | Xilio Therapeutics, Inc. XLO |
FMR CORP | 1,907,671 6.944% |
-662,599 (-25.78%) |
Filing History |
| 2023-01-25 4:01 pm Purchase |
2022-12-31 | 13G | Xilio Therapeutics, Inc. XLO |
Octagon Capital Advisors LP | 2,425,000 8.830% |
2,425,000 (New Position) |
Filing History |
| 2022-12-29 5:24 pm Sale |
2022-12-29 | 13G | Xilio Therapeutics, Inc. XLO |
Flynn James E | 0 0.000% |
-2,154,061 (Position Closed) |
Filing History |
| 2022-11-14 4:43 pm Sale |
2022-11-14 | 13G | Xilio Therapeutics, Inc. XLO |
RA Capital Management, L.P. | 0 0.000% |
-2,002,217 (Position Closed) |
Filing History |
| 2022-02-14 4:11 pm Purchase |
2021-12-31 | 13G | Xilio Therapeutics, Inc. XLO |
RA Capital Management, L.P. | 2,002,217 7.300% |
469,450 (+30.63%) |
Filing History |
| 2022-02-14 06:42 am Unchanged |
2021-12-31 | 13G | Xilio Therapeutics, Inc. XLO |
Bain Capital Life Sciences Fund II, L.P. | 1,348,682 4.900% |
0 (Unchanged) |
Filing History |